ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Química Nova (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422020000200212 |
Resumo: | Limitations of conventional treatment and dosage forms prompted the investigation of novel approaches that combine efficacy, selectivity and fewer adverse effects. These are the main promises of nanomedicine, generally defined as the application of nanotechnology to the biomedical field. Despite the considerable advances over the years and the large number of publications resulting from the growth of nanomedicine, there are still many hurdles and unknown factors limiting its successful translation from promise to reality. These factors range from the lack of standardization in the terminology and regulations, to the lack of understanding of interactions between nanocarriers and the biological system, and their influence on drug pharmacodynamics. In this manuscript, we aim at presenting and discussing concepts and terminologies used in the nanomedicine field and examining the main types of nanocarriers and their effects to modulate biological barriers and aid drug transport, bioavailability and targeting. |
id |
SBQ-3_60d3710b2d6669c373ea157a897f5849 |
---|---|
oai_identifier_str |
oai:scielo:S0100-40422020000200212 |
network_acronym_str |
SBQ-3 |
network_name_str |
Química Nova (Online) |
repository_id_str |
|
spelling |
ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’nanocarriersnanomedicinebiological barriersnanopharmacologyLimitations of conventional treatment and dosage forms prompted the investigation of novel approaches that combine efficacy, selectivity and fewer adverse effects. These are the main promises of nanomedicine, generally defined as the application of nanotechnology to the biomedical field. Despite the considerable advances over the years and the large number of publications resulting from the growth of nanomedicine, there are still many hurdles and unknown factors limiting its successful translation from promise to reality. These factors range from the lack of standardization in the terminology and regulations, to the lack of understanding of interactions between nanocarriers and the biological system, and their influence on drug pharmacodynamics. In this manuscript, we aim at presenting and discussing concepts and terminologies used in the nanomedicine field and examining the main types of nanocarriers and their effects to modulate biological barriers and aid drug transport, bioavailability and targeting.Sociedade Brasileira de Química2020-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422020000200212Química Nova v.43 n.2 2020reponame:Química Nova (Online)instname:Sociedade Brasileira de Química (SBQ)instacron:SBQ10.21577/0100-4042.20170481info:eu-repo/semantics/openAccessApolinário,Alexsandra ConceiçãoSalata,Giovanna CassoneBianco,Arthur F. R.Fukumori,ClaudioLopes,Luciana Biaginipor2020-05-12T00:00:00Zoai:scielo:S0100-40422020000200212Revistahttps://www.scielo.br/j/qn/ONGhttps://old.scielo.br/oai/scielo-oai.phpquimicanova@sbq.org.br1678-70640100-4042opendoar:2020-05-12T00:00Química Nova (Online) - Sociedade Brasileira de Química (SBQ)false |
dc.title.none.fl_str_mv |
ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’ |
title |
ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’ |
spellingShingle |
ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’ Apolinário,Alexsandra Conceição nanocarriers nanomedicine biological barriers nanopharmacology |
title_short |
ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’ |
title_full |
ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’ |
title_fullStr |
ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’ |
title_full_unstemmed |
ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’ |
title_sort |
ABRINDO A CAIXA DE PANDORA DOS NANOMEDICAMENTOS: HÁ REALMENTE MUITO MAIS ‘ESPAÇO LÁ EMBAIXO’ |
author |
Apolinário,Alexsandra Conceição |
author_facet |
Apolinário,Alexsandra Conceição Salata,Giovanna Cassone Bianco,Arthur F. R. Fukumori,Claudio Lopes,Luciana Biagini |
author_role |
author |
author2 |
Salata,Giovanna Cassone Bianco,Arthur F. R. Fukumori,Claudio Lopes,Luciana Biagini |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Apolinário,Alexsandra Conceição Salata,Giovanna Cassone Bianco,Arthur F. R. Fukumori,Claudio Lopes,Luciana Biagini |
dc.subject.por.fl_str_mv |
nanocarriers nanomedicine biological barriers nanopharmacology |
topic |
nanocarriers nanomedicine biological barriers nanopharmacology |
description |
Limitations of conventional treatment and dosage forms prompted the investigation of novel approaches that combine efficacy, selectivity and fewer adverse effects. These are the main promises of nanomedicine, generally defined as the application of nanotechnology to the biomedical field. Despite the considerable advances over the years and the large number of publications resulting from the growth of nanomedicine, there are still many hurdles and unknown factors limiting its successful translation from promise to reality. These factors range from the lack of standardization in the terminology and regulations, to the lack of understanding of interactions between nanocarriers and the biological system, and their influence on drug pharmacodynamics. In this manuscript, we aim at presenting and discussing concepts and terminologies used in the nanomedicine field and examining the main types of nanocarriers and their effects to modulate biological barriers and aid drug transport, bioavailability and targeting. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-02-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422020000200212 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-40422020000200212 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
10.21577/0100-4042.20170481 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
publisher.none.fl_str_mv |
Sociedade Brasileira de Química |
dc.source.none.fl_str_mv |
Química Nova v.43 n.2 2020 reponame:Química Nova (Online) instname:Sociedade Brasileira de Química (SBQ) instacron:SBQ |
instname_str |
Sociedade Brasileira de Química (SBQ) |
instacron_str |
SBQ |
institution |
SBQ |
reponame_str |
Química Nova (Online) |
collection |
Química Nova (Online) |
repository.name.fl_str_mv |
Química Nova (Online) - Sociedade Brasileira de Química (SBQ) |
repository.mail.fl_str_mv |
quimicanova@sbq.org.br |
_version_ |
1750318120128479232 |